LFG
NRIX icon

Larson Financial Group’s Nurix Therapeutics NRIX Stock Holding History

Larson Financial Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.9K Sell
445
-1,096
-71% -$18.2K ﹤0.01% 2440
2025
Q4 		$29.2K Buy
1,541
+1,190
+339% +$17.1K ﹤0.01% 1498
2025
Q3 		$3.24K Buy
+351
New +$3.65K ﹤0.01% 2516
2024
Q4 		– Sell
-24
Closed -$539 – 2860
2024
Q3 		$539 Buy
+24
New +$544 ﹤0.01% 2106

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Larson Financial Group's NRIX Position: Q1 2026 in Review

Larson Financial Group reduced its Nurix Therapeutics (NRIX) stake by 71% in Q1 2026, selling an estimated $18.2K and leaving 445 shares worth $6.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2440.

Larson Financial Group first reported a position in NRIX in Q3 2024 and has held it in 4 quarters since. The position peaked at $29.2K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Larson Financial Group held 445 shares of Nurix Therapeutics worth $6.9K as of Q1 2026.
  • Larson Financial Group sold 1,096 Nurix Therapeutics shares in Q1 2026, an estimated $18.2K.
  • Nurix Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2440 holding.
  • Larson Financial Group first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Larson Financial Group's Nurix Therapeutics position peaked at $29.2K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.